| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | THSD1 |
| Uniprot No | Q9NS62 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-361aa |
| 氨基酸序列 | EYLLLREPGHVALSNDTVYVDFQYFDGANGTLRNVSVLLLEANTNQTVTT KYLLTNQSQGTLKFECFYFKEAGDYWFTMTPEATDNSTPFPWWEKSAFLK VEWPVFHVDLNRSAKAAEGTFQVGLFTSQPLCPFPVDKPNIVVDVIFTNS LPEARRNSRQPLEIRTSKRTELAQGQWVEFGCAPLGPEAYVTVVLKLLGR DSVITSTGPIDLAQKFGYKLVMVPELTCESGVEVTVLPPPCTFVQGVVTV FKEAPRYPGKRTIHLAENSLPLGERRTIFNCTLFDMGKNKYCFDFGISSR SHFSAKEECMLIQRNTAFQPSSPSPLQPQGPVKSNNIVDHHHHHH |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于THSD1重组蛋白的3篇参考文献的简要信息(注：以下文献信息为模拟示例，实际文献需通过学术数据库查询确认)：
1. **文献名称**: "THSD1 promotes endothelial cell migration and angiogenesis via integrin-mediated signaling"
**作者**: Zhang Y, et al.
**摘要**: 研究报道了重组THSD1蛋白在体外促进内皮细胞迁移和血管生成的作用，揭示了其通过整合素αvβ3激活FAK信号通路的分子机制。
2. **文献名称**: "Recombinant THSD1 attenuates cerebral ischemia-reperfusion injury by modulating blood-brain barrier permeability"
**作者**: Li H, et al.
**摘要**: 该研究利用原核表达系统制备了重组THSD1蛋白，发现其能通过保护血脑屏障完整性减轻小鼠脑缺血再灌注损伤，提示其潜在治疗价值。
3. **文献名称**: "Structural characterization of the thrombospondin type-1 repeat domain of THSD1 and its role in cell adhesion"
**作者**: Chen X, Wang L.
**摘要**: 通过杆状病毒表达系统获得高纯度THSD1重组蛋白，解析其TSP-1结构域的三维结构，并证明该结构域通过结合细胞表面受体调控细胞黏附功能。
---
**注意**：以上为基于THSD1已知生物学功能生成的模拟文献，真实文献需通过PubMed(https://pubmed.ncbi.nlm.nih.gov/)或Google Scholar等平台检索确认。实际研究中，THSD1重组蛋白相关研究可能涉及其在血管稳态、细胞外基质互作或疾病模型中的应用。
THrombospondin type-1 domain-containing protein 1 (THSD1) is a transmembrane glycoprotein belonging to the thrombospondin family, characterized by conserved thrombospondin type-1 repeats (TSRs) that mediate cell-matrix interactions. Initially identified for its structural homology to thrombospondins, THSD1 has gained attention for its roles in vascular biology, neuronal development, and cancer progression. The protein is composed of an N-terminal signal peptide, multiple TSR domains, and a C-terminal transmembrane domain, enabling its involvement in extracellular matrix (ECM) remodeling, cell adhesion, and signaling pathways.
Recombinant THSD1 protein is engineered through heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to study its biochemical and functional properties. Purified THSD1 retains bioactive domains critical for binding integrins, growth factors, or ECM components, making it a valuable tool for in vitro assays investigating angiogenesis, cell migration, or tumor microenvironment interactions. Studies suggest THSD1 modulates VEGF and TGF-β signaling, influencing endothelial cell behavior and vascular stability. In neuroscience, it regulates axonal guidance and synaptic plasticity via interactions with neuronal receptors.
Dysregulation of THSD1 is implicated in pathologies such as preeclampsia (via placental vascular dysfunction) and glioblastoma (through ECM-mediated invasion). Recombinant forms enable mechanistic studies, antibody development, and therapeutic exploration. However, challenges remain in optimizing post-translational modifications (e.g., glycosylation) to preserve native functionality. Current research focuses on clarifying its dual roles in physiological homeostasis versus disease contexts, leveraging recombinant protein tools to dissect molecular pathways and therapeutic potential.
×
